Although these patients may be expected to have progression and survival rates comparable to those of patients with clinical advanced clinical disease, as defined by grade and serum prostate-specific antigen (PSA) level, those men who present with clinical stage T3 are likely to have greater tumour volume, higher grade and increased likelihood of regional spread. Here, KLK3 is linked to neoplasm.